Premium
Prostaglandin E 2 inhibits neutrophil extracellular trap formation through production of cyclic AMP
Author(s) -
Shishikura Kyosuke,
Horiuchi Takahiro,
Sakata Natsumi,
Trinh DucAnh,
Shirakawa Ryutaro,
Kimura Tomohiro,
Asada Yujiro,
Horiuchi Hisanori
Publication year - 2016
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13373
Subject(s) - receptor , extracellular , neutrophil extracellular traps , agonist , prostaglandin e2 , prostaglandin e2 receptor , chemistry , rolipram , prostaglandin e , in vitro , stimulation , in vivo , microbiology and biotechnology , enzyme , biochemistry , medicine , endocrinology , biology , phosphodiesterase , inflammation , immunology
Background and Purpose Upon stimulation, neutrophils release their nuclear contents called neutrophil extracellular traps (NETs), which contain unfolded chromatin and lysosomal enzymes. NETs have been demonstrated to play a critical role in host defence, although the role of PGE 2 , a bioactive substance generated in inflammatory tissues, in the formation of NETs remains unclear. Experimental Approach The effects of PGE 2 , agonists and antagonists of its receptors, and modulators of the cAMP–PKA pathway on the formation of NETs were examined in vitro in isolated neutrophils and in vivo in a newly established mouse model. Key Results PGE 2 inhibited PMA‐induced NET formation in vitro through EP 2 and EP 4 Gαs‐coupled receptors. Incubation with a cell‐permeable cAMP analogue, dibutyryl cAMP, or various inhibitors of a cAMP‐degrading enzyme, PDE, also suppressed NET formation. In the assay established here, where an agarose gel was s.c. implanted in mice and NET formation was detected on the surface of the gel, the extent of the NET formed was inhibited in agarose gels containing rolipram, a PDE4 inhibitor, and butaprost, an EP 2 receptor agonist. Conclusions and Implications PGE 2 inhibits NET formation through the production of cAMP. These findings will contribute to the development of novel treatments for NETosis‐related diseases.